A Scandi cafe in the southeast is now open at night for steak carbonara, share plates and more
Scandinavian$$$$
At Oppen, while the inspiration is Denmark, the menu is a marvellous Melbourne mash-up so there was no doubt avocado had to make an appearance – smashed, dolloped over toast, and further dressed up with Danish feta and dukkah. So far, so cafe, right? But then it gets radical.
Vegemite and avocado are BFFs – the spread's salt and the avo's creamy sweetness play so nicely. Yet Oppen does not merely scoop black gold out of the jar. Instead, they take it up a notch or five by spreading the 'Mite super thin on baking paper and dehydrating it for three days, thus transforming inky sludge into translucent black shards. These paper-thin slivers are showered over the whole shebang, bringing visual excitement and crisp, textural play to a classic flavour combination.
With its candlelight, glowing lamps and flowing curtains, Oppen also easily shifts from day to night with its new evening opening hours from Thursday to Saturday. On Thursdays, try the $25 special of steak on carbonara, which started as an insider favourite. You can also get the pasta on its own – one of three on offer – alongside wine bar-style plates designed to share.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
West Australian
12-08-2025
- West Australian
CME WA picks BHP iron ore boss Tim Day to take over presidency from outgoing Rio Tinto iron boss Simon Trott
BHP's Tim Day has succeeded London-bound Simon Trott as the new president of the Chamber of Minerals and Energy WA. Mr Day, BHP WA iron ore asset president, has taken the reins from Mr Trott — who has stepped down from the role at the mining lobby group a fortnight before he formally starts his new job as Rio Tinto's chief executive. Mr Trott and Mr Day spent the 2025 financial year as rivals — both were in charge of the Pilbara iron ore mines that generate the majority of profit for BHP and Rio. The two mining giants are by far the two largest iron ore producers in Australia. Hancock Prospecting chief executive Sanjiv Manchanda was also believed to be a contender. Mr Manchanda, who has been a key lieutenant of Gina Rinehart for two decades, is currently a vice president at CME along with Northern Star Resources founder Bill Beament. 'I'm honoured to take on the role of CME President at a time of great opportunity for Western Australian resources,' Mr Day said. 'The mining and energy sectors here in WA are leading the world through operational excellence, innovation and technology. As the biggest employer in the state, we provide jobs across our operations from the Pilbara to the Goldfields, and the South West to the Kimberley. Our impact is felt around Australia and the world. 'I look forward to working with the executive council and our members to support the continued growth and global leadership of WA's resources sector.' Mr Day has been the chief of BHP's most lucrative division since February last year. Mr Trott was appointed to the CME presidency in April last year while serving as the chief of Rio's WA iron ore division. CME chief executive Rebecca Tomkinson, who is also London bound, welcomed Mr Day to the role. 'Tim's involvement with CME on our Advisory Board and Executive Committee has highlighted his experience and knowledge as a leader in the mining and resources sector,' Ms Tomkinson said. 'He takes on the presidency at a time of great opportunity but also challenges for the sector. It's a highly pivotal leadership role and one that's instrumental in holding policy makers to account on behalf of industry.' Ms Tomkinson is set to leave her post at CME next month to be the State Government's new trade ambassador in the United Kingdom. She paid tribute to a fellow inbound Londoner. 'Simon is one of Australia's leading resources executives and has played a significant role shaping WA's world-leading iron ore sector,' Ms Tomkinson said. 'His vision and leadership have been invaluable assets to CME for the entire time he has served on the advisory board, and particularly during his tenure as president.' Mr Trott was promoted to the top job at Rio in May, taking over from Danish native Jakob Stausholm.
AU Financial Review
31-07-2025
- AU Financial Review
How Ozempic's maker lost the weight loss fight
Until a year ago, Danish drugmaker Novo Nordisk was riding high. It had been first to market with an injectable diabetes treatment and the name Ozempic quickly became shorthand for new class of blockbuster weight loss drugs. But competition started to catch up, a new drug trial disappointed, shares and growth fell and its chief executive departed in May. Then this week a major profit warning knocked more than €60 billion ($106 billion) off its value. The company also announced that senior executive Maziar Mike Doustdar would become the new CEO.
Sydney Morning Herald
29-07-2025
- Sydney Morning Herald
Ozempic maker takes $107 billion hit as alarm bells ring louder
Investors wiped $US70 billion ($107 billion) off Novo Nordisk's market value after the maker of Ozempic and Wegovy issued a profit warning and named a new CEO, as it battles rising competition in the obesity drug market. Novo named Maziar Mike Doustdar as its new chief executive, turning to a veteran insider to revive sales and reassure investors rattled by fears the Danish drugmaker is losing ground in the obesity drug race it started. Doustdar's appointment failed to stem a stock market rout sparked by Novo slashing its outlook for 2025 sales growth to between 8 per cent and 14 per cent, from between 13 per cent and 21 per cent previously. Its shares plunged nearly 30 per cent before paring some losses to trade down over 20 per cent by mid-afternoon. The shares are now down 44 per cent this year. 'The magnitude of the guidance cut is a shocker,' Markus Manns, a portfolio manager at mutual fund firm Union Investment, a Novo shareholder, told Reuters, adding that Novo's issues went deeper than 'compounded' copycats to Wegovy. Compounded drugs are custom-made medicines that are based on the same ingredients as branded drugs. Novo has been hit by copycats of its GLP-1 drugs Wegovy for weight-loss and Ozempic for diabetes. US law bars pharmacies from replicating approved drugs, but has allowed 'compounding' for patients needing custom doses or formulations. Loading The company said in a statement that it cut its 2025 sales outlook due to lower growth expectations in the second half in the US, both for Wegovy and Ozempic in the GLP-1 diabetes market. The drugmaker, which became Europe's most valuable listed company following the launch of Wegovy in 2021, is now facing a reckoning as it looks to turn things around after the abrupt removal in May of CEO Lars Fruergaard Jorgensen.
